Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab in Advanced Endometrial Carcinoma
NCT00006089Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2000
- Primary completion
- Sep 2007
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in endometrial adenocarcinoma, sponsored by National Cancer Institute. Started Sep 2000; status: completed.
02
Drugs
03
Conditions
endometrial adenocarcinoma
Beyond the preview
Go deeper on NCT00006089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006089.